<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466399</url>
  </required_header>
  <id_info>
    <org_study_id>LipoLat-CS202</org_study_id>
    <nct_id>NCT02466399</nct_id>
  </id_info>
  <brief_title>POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma</brief_title>
  <official_title>An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Ophthalmic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Ophthalmic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, multi-center, active-controlled parallel-comparison of&#xD;
      POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary&#xD;
      open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The mean change from baseline intraocular pressure at 3 months (0800 hrs)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>POLAT-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost liposome ophthalmic injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost ophthalmic solution 0.005%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POLAT-001</intervention_name>
    <description>Subconjunctival injection</description>
    <arm_group_label>POLAT-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost ophthalmic solution</intervention_name>
    <description>Latanoprost ophthalmic solution q.d., evening</description>
    <arm_group_label>Latanoprost ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 year of age or greater.&#xD;
&#xD;
          2. Diagnosis of primary open angle glaucoma (OAG) or ocular hypertension (OHT).&#xD;
&#xD;
          3. Unmedicated (post-washout) intraocular pressure (IOP) ≥ 24 mm Hg at 2 eligibility&#xD;
             visits (0800 hr), 2-7 days apart. If both eyes meet the IOP criteria, the eye with the&#xD;
             higher IOP at Visit 1 will be designated as the study eye. If IOP in both eyes is the&#xD;
             same, the right eye will be designated as the study eye. Note that both eyes will be&#xD;
             treated.&#xD;
&#xD;
          4. Corrected visual acuity at Visit -1 in each eye +1.0 logarithm of minimum angle of&#xD;
             resolution (logMAR) or better by Early Treatment of Diabetic Retinopathy Study (ETDRS)&#xD;
             in each eye (equivalent to 20/200).&#xD;
&#xD;
          5. Able and willing to give signed informed consent and follow study instructions.&#xD;
&#xD;
          6. Subjects must have a documented history of ≥ 20% IOP reduction O.U. using any topical&#xD;
             ocular prostaglandin/prostamide ocular hypotensive medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic&#xD;
&#xD;
          1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure&#xD;
             or narrow angles judged to be occludable by the investigator. Note: Previous laser&#xD;
             peripheral iridotomy is NOT acceptable.&#xD;
&#xD;
          2. IOP &gt; 36 mm Hg in either eye at any pre-randomization study visit.&#xD;
&#xD;
          3. Known corticosteroid-responder as judged by investigator.&#xD;
&#xD;
          4. Known hypersensitivity to any component of the Investigational Product formulation&#xD;
             (benzalkonium chloride, etc.), fluoroquinolone ophthalmic solution, or topical&#xD;
             anesthetics, Povidone Iodine antiseptic, or diagnostic eye drops.&#xD;
&#xD;
          5. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye.&#xD;
&#xD;
          6. Refractive surgery in either eye .&#xD;
&#xD;
          7. Ocular trauma, extraocular or intraocular surgery or laser treatment within the past&#xD;
             six months in either eye.&#xD;
&#xD;
          8. Evidence of ocular infection, inflammation, clinically significant blepharitis or&#xD;
             conjunctivitis at baseline (Visit 1), or a history of herpes simplex keratitis in&#xD;
             either eye. Note: mild blepharitis, allergy and dry eye is acceptable.&#xD;
&#xD;
          9. Ocular medication of any kind within 30 days of Visit 1 in either eye, with the&#xD;
             exception of a) ocular hypotensive therapy (which must be washed out according to the&#xD;
             provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 1)&#xD;
             or c) lubricating drops for dry eye (which may be used throughout the study).&#xD;
&#xD;
         10. Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis&#xD;
             sicca) in either eye which might interfere with the study, including glaucomatous&#xD;
             damage so severe that washout of ocular hypotensive medications for one month is not&#xD;
             judged safe by the investigator (i.e., cup-disc ratio &gt; 0.8).&#xD;
&#xD;
         11. Central corneal thickness greater than 600 µm in either eye.&#xD;
&#xD;
         12. Any ocular abnormality preventing reliable applanation tonometry of either eye.&#xD;
&#xD;
         13. Significant media opacity in either eye that would exclude adequate posterior segment&#xD;
             examination&#xD;
&#xD;
         14. Contraindications to pupil dilation in either eye.&#xD;
&#xD;
         15. Unwillingness to accept known adverse events of latanoprost such as eyelid and/or iris&#xD;
             pigmentation, eyelash growth, etc.&#xD;
&#xD;
         16. History of macular edema, including cystoid macular edema, or current or recent (6&#xD;
             months) uveitis.&#xD;
&#xD;
         17. Planned intraocular surgery in either eye during study participation&#xD;
&#xD;
             Systemic:&#xD;
&#xD;
         18. Clinically significant abnormalities (as determined by the treating physician) in&#xD;
             laboratory tests at screening.&#xD;
&#xD;
         19. Known hypersensitivity or systemic contraindication to latanoprost or components of&#xD;
             study medication.&#xD;
&#xD;
         20. Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal,&#xD;
             endocrine or cardiovascular disorders), which might interfere with the study.&#xD;
&#xD;
         21. Participation in any investigational study within 30 days prior to baseline.&#xD;
&#xD;
         22. Changes of systemic medication that could have a substantial effect on IOP within 30&#xD;
             days prior to screening, or anticipated during the study.&#xD;
&#xD;
         23. Any individual the investigator believes might suffer physical or mental harm by&#xD;
             participating in this trial. Due to the current status of the preclinical safety&#xD;
             program, women of childbearing potential who are pregnant, nursing, planning a&#xD;
             pregnancy, or not using a medically acceptable form of birth control. An adult woman&#xD;
             is considered to be of childbearing potential unless she is one year post-menopausal&#xD;
             or three months post-surgical sterilization. All females of childbearing potential&#xD;
             must have a negative urine pregnancy test result at the Visit 1 examination and must&#xD;
             agree to use an acceptable method of contraception during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina T Wong, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Peregrine Ophthalmic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Professional Research Network</name>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <zip>29445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>POLAT-001</title>
          <description>Latanoprost liposome ophthalmic injection&#xD;
POLAT-001: Subconjunctival injection</description>
        </group>
        <group group_id="P2">
          <title>Latanoprost Ophthalmic Solution</title>
          <description>latanoprost ophthalmic solution 0.005%&#xD;
Latanoprost ophthalmic solution: Latanoprost ophthalmic solution q.d., evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early exit due to family emergency</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>POLAT-001</title>
          <description>Latanoprost liposome ophthalmic injection&#xD;
POLAT-001: Subconjunctival injection</description>
        </group>
        <group group_id="B2">
          <title>Latanoprost Ophthalmic Solution</title>
          <description>latanoprost ophthalmic solution 0.005%&#xD;
Latanoprost ophthalmic solution: Latanoprost ophthalmic solution q.d., evening</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="9.39"/>
                    <measurement group_id="B2" value="63.1" spread="11.69"/>
                    <measurement group_id="B3" value="63.9" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months</title>
        <description>The mean change from baseline intraocular pressure at 3 months (0800 hrs)</description>
        <time_frame>3 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>POLAT-001</title>
            <description>Latanoprost liposome ophthalmic injection&#xD;
POLAT-001: Subconjunctival injection</description>
          </group>
          <group group_id="O2">
            <title>Latanoprost Ophthalmic Solution</title>
            <description>latanoprost ophthalmic solution 0.005%&#xD;
Latanoprost ophthalmic solution: Latanoprost ophthalmic solution q.d., evening</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months</title>
          <description>The mean change from baseline intraocular pressure at 3 months (0800 hrs)</description>
          <population>Per protocol</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="4.6"/>
                    <measurement group_id="O2" value="-6.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>POLAT-001</title>
          <description>Latanoprost liposome ophthalmic injection&#xD;
POLAT-001: Subconjunctival injection</description>
        </group>
        <group group_id="E2">
          <title>Latanoprost Ophthalmic Solution</title>
          <description>latanoprost ophthalmic solution 0.005%&#xD;
Latanoprost ophthalmic solution: Latanoprost ophthalmic solution q.d., evening</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bone and bladder cancer</sub_title>
                <description>Neoplasms benign, malignant and unspecified (incl cysts and polyps) (Bladder cancer)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Instillation site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If multi-center study publication not published within two (2) years after the completion of the Study at all sites, Investigator may publish the results of the Study obtained by Investigator with 60 days notice to Sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>Peregrine Ophthalmic Pte Ltd</organization>
      <phone>65 97914382</phone>
      <email>jchua@peregrineop.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

